ReviewClinical and experimental vaccine research2019
Rhoptry antigens as
Review in Clinical and experimental vaccine research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 68 citations in OpenAlex.
- ROP64-DeficientMicroorganisms · 2026Article
- Heterologous Prime-Boost Vaccination with GRA35-Encoding DNA and mRNA Vaccines Enhances Protective Immunity AgainstMicroorganisms · 2026Article
- Recombinant ROP8 antigen: diagnostics, immunogenicity, and therapeutic targeting in toxoplasmosis.Frontiers in immunology · 2026Article
- Nanoparticle-Based Vaccines Against Toxoplasma gondii: Immunological Rationale, Platform Strategies, and Translational Challenges.Transboundary and emerging diseases · 2026Review
- Recombinant ROP6 protein expressed in Saccharomyces cerevisiae INVSc1 cells induced strong immune response and provided significant protection against toxoplasmosis.Scientific reports · 2025Article
- Considerations on Structural Vaccinology and Epitope Screening of Calcium-Dependent Protein Kinases 8 as a Potential Vaccine Target AgainstInterdisciplinary perspectives on infectious diseases · 2025Article
- In Silico-Based Investigation of the Immunogenicity and Biochemical Attributes ofJournal of parasitology research · 2025Article
- Article
- Structural Prediction and Antigenic Analysis of ROP18, MIC4, and SAG1 Proteins to Improve Vaccine Design againstInfectious disorders drug targets · 2025Article
- Vaccination with a DNA vaccine cocktail encoding TgROP2, TgROP5, TgROP9, TgROP16, TgROP17, and TgROP18 confers limited protection against Toxoplasma gondii in BALB/c mice.Parasitology research · 2024Article
- Recombinant SAG2A Protein fromMicroorganisms · 2024Article
- Completing the pieces of a puzzle: in-depth probing ofClinical and experimental vaccine research · 2024Article
- Construction and biological function ofZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Article
- Effective factors in the pathogenesis ofHeliyon · 2024Review
- Immunogenicity and protective efficacy of recombinant chimeric antigens based on surface proteins ofFrontiers in immunology · 2024Article
- In Silico Analysis of the ROP29 Protein as a Vaccine Candidate AgainstJournal of parasitology research · 2024Article
- Toxoplasma rhoptry proteins that affect encephalitis outcome.Cell death discovery · 2023Review
- CD4Vaccines · 2023Article
- Article
- Cerebral toxoplasmosis in HIV-infected patients: a review.Pathogens and global health · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxoplasmosis is a cosmopolitan zoonotic infection, caused by a unicellular protozoan parasite known as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.